Table 2.
Association Between the Use and Timing of Corticosteroid Therapy With Visual Disability by Month 6
| Use corticosteroids | No corticosteroids (n = 16) | High-dose corticosteroids (n = 58) | p Value |
| HCVA (logMar) | −0.04 (−0.07 to 0) | 0 (0.055 to 0.1) | 0.043 |
| 2.5% LCVA | 24 (14.2 to 30.2) | 19 (3 to 28) | 0.167 |
| Color vision | 36 (35.5 to 36) | 36 (31.2 to 36) | 0.125 |
| VFQ25 global | NA | 92.7 (87.4 to 96.3) | — |
| VFQ25 + 10neuro | NA | 75.1 (64.1 to 83.2) | — |
| Onset corticosteroids | ≤10 d (n = 37) | >10 d (n = 21) | p Value |
| HCVA LogMar | 0.01 (−0.06 to 0.1) | 0 (−0.03, 0.09) | 0.852 |
| 2.5% LCVA | 19 (4.5 to 28) | 12.5 (0, 26.8) | 0.511 |
| Color vision | 36 (31.2 to 36) | 35 (31.5, 36) | 0.738 |
| VFQ25 global | 92.8 (87.6 to 97.2) | 91.3 (87.4 to 95.1) | 0.376 |
| VFQ25 + 10neuro | 76.4 (60.9 to 83.8) | 75 (70.1 to 80.7) | 0.734 |
Abbreviations: EDSS = Expanded Disability Status Scale; HCVA = high-contrast visual acuity using EDTRS charts; HRR = Hardy Rand and Rittler Pseudoisochromatic Plates; LCVA = low-contrast visual acuity using 2.5% contrast Sloan charts; VEP = visual evoked potential; VFQ25 = Visual function questionnaire.
Data are shown as mean and interquartile range (IQR).